Optimization of Sterically stabilized liposome using design of experiment approach

Authors

  • Dasharath M. Patel Graduate School of Pharmacy, Gujarat Technological University, GTU Gandhinagar Campus, K-6 Circle, E-4 Electronic Estate, Sector-26, Gandhinagar-382028, Gujarat, India
  • Niteshkumar Patel Department of Pharmaceutical Sciences, Hemchandracharya North Gujarat University, Patan-384265, Gujarat, India

Abstract

Recently, a drug delivery system with controlled and targeted drug release at the tumor sites emerged as an attractive option for improving anticancer therapeutics. Advanced nanotherapeutics must not be limited to nanoscale, but should find their way to target the solid tumor via direct or indirect way. Pegylation on the surface of liposome helps to become liposome as long-circulating and indirect or passive targeting to tumors. The purpose of this study is to develop and optimize the critical process parameters, which play an important role in the quality pegylated liposome. The design of experiment (DoE) was used to study the impact of critical process variables like hydration temperature, extrusion process temperature, ethanol concentration, drug loading temperature, and drug loading time. Pegylated liposome was prepared using the ethanol injection method. Size reduction was achieved using the extrusion method. Drug encapsulation was achieved by a remote loading method using an ammonium phosphate gradient. A fractional factorial design was chosen for the optimization of process variables. Hydration temperature and extrusion process temperature directly impact on the degradation of lipids used in liposome formation. Higher temperature increases the lipid degradation during the process. The concentration of ethanol during the size reduction process inversely affects the particle size of the liposome. Higher the ethanol content lowers the particle size achieved. The temperature during drug loading process directly affects the degradation of the drug while inversely affect the encapsulation property. Stability study indicates that optimized formulation using DoE approach remains stable. The present research confirms the feasibility of developing and optimizing sterically stabilized liposome using DoE approach.

Keywords:

Vincristine, Sterically stabilized liposome, Pegylated liposome, design of experiment, remote loading.

DOI

https://doi.org/10.25004/IJPSDR.2020.120405

References

Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual review of pharmacology and toxicology. 1999;39:1-17.

Courjault F, Leroy D, Coquery I, Toutain H. Platinum complex induced dysfunction of cultured renal proximal tubule cells. Archives of toxicology. 1993;67(5):338-346.

Morgan MT, Carnahan MA, Immoos CE, Ribeiro AA, Finkelstein S, Lee SJ, et al. Dendritic molecular capsules for hydrophobic compounds. Journal of the American Chemical Society. 2003; 125(50):15485-15489.

Mueller CE. Prodrug approaches for enhancing the bioavailability of drugs w ith low solubilit y. Chemistr y and Biodiversit y. 2009;6(11):2071-2083.

Duncan R. The dawning era of polymer therapeutics. Nature reviews Drug discovery. 2003;2(5):347.

Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery. 2005;4(2):145.

Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology. 2007;2(12):751.

Yoo J-W, Ir vine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nature reviews Drug discovery. 2011;10(7):521.

Fox ME, Szoka FC, Fréchet JM. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Accounts of chemical research. 2009;42(8):1141-1151.

Carbone PP, Bono V, Frei Iii E, Brindley CO. Clinical studies with vincristine. Blood. 1963;21(5):640-647.

Horton JK, Houghton PJ, Houghton JA. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochemical Pharmacology. 1988;37(20):3995-4000.

El-Sayed A, Cordell GA. Catharanthus, alkaloids. XXXIV. Catharanthamine, a new antitumor bisindole alkaloid from Catharanthus roseus. Journal of Natural Products. 1981;44(3):289-293.

Moore A, Pinkerton R. Vincristine: Can its therapeutic index be enhanced? Pediatric Blood and Cancer. 2009;53(7):1180-1187.

Webb M, Harasym T, Masin D, Bally M, Mayer L. Sphingomyelincholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. British Journal of Cancer. 1995;72(4):896-904.

Zhu G, Oto E, Vaage J, Quinn Y, Newman M, Engbers C, et al. The effect of vincristine–polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity. Cancer Chemotherapy and Pharmacology. 1996;39(1-2):138-142.

Sivakumar P, Rao KP. The use of cholesteryl pullulan for the preparation of stable vincristine liposomes. Carbohydrate Polymers. 2003;51(3):327-332.

Boehlke L, Winter JN. Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug. Expert Opinion on Biological Therapy. 2006;6(4):409-415.

Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemot herapy and Pharmacology. 2013;71(3):555-564.

Harrison TS, Lyseng-Williamson KA. Vincristine sulfate liposome injection. BioDrugs. 2013;27(1):69-74.

Monte WT, Abra RM, Luo B, Zhang Y. A ready-to-use formulation for vincristine sulfate liposome injection. Google Patents. 2018.

Webb MS, Sarris AH, Cabanillas F, Mayer LD, Bally MB, Burge C, et al. Clinical and preclinical pharmacology of liposomal vincristine. Journal of Liposome Research. 2000;10(4):501-512.

Yang Y, Guo Y, Tan X, He H, Zhang Y, Yin T, et al. Vincristine-loaded liposomes prepared by ion-paring techniques: Effect of lipid, pH and antioxidant on chemical stability. European Journal of Pharmaceutical Sciences. 2018;111:104-112.

Yan Z , Zhu Z-l, Qian Z-z, Hu G, Wang H-q, Liu W-h, et al. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors. Acta Pharmacologica Sinica. 2012;33(6):852-858.

Webb MS, Bally MB, Mayer LD, Miller JJ, Tardi PG. Sphingosomes for enhanced drug delivery. Google Patents; 1998.

Kale J, Ryan Jr HE, Wang L, editors. Debt as a bonding mechanism: Evidence from the relations between employee productivity, capital structure, and outside employment opportunities. 18th Annual Conference on Financial Economics and Accounting , NYU; 2007.

Vickers NJ. Animal Communication: When I’m Calling You, Will You Answer Too? Current Biology. 2017;27(14):R713-R715.

Jiang W, Lionberger R, Yu LX. In vitro and in vivo characterizations of pegylated liposomal doxorubicin. Bioanalysis. 2011;3(3):333-344.

Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Research. 2006;66(6):3271-3277.

Hong K, Drummond DC, Kirpotin D. Liposomes useful for drug delivery. Google Patents. 2012.

Zucker D, Marcus D, Barenholz Y, Goldblum A. Liposome drugs’ loading efficiency: a working model based on loading conditions and drug’s physicochemical properties. Journal of Controlled Release. 2009;139(1):73-80.

Published

30-07-2020
Statistics
Abstract Display: 436
PDF Downloads: 533
Dimension Badge

How to Cite

“Optimization of Sterically Stabilized Liposome Using Design of Experiment Approach”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 12, no. 4, July 2020, pp. 331-43, https://doi.org/10.25004/IJPSDR.2020.120405.

Issue

Section

Research Article

How to Cite

“Optimization of Sterically Stabilized Liposome Using Design of Experiment Approach”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 12, no. 4, July 2020, pp. 331-43, https://doi.org/10.25004/IJPSDR.2020.120405.

Similar Articles

1-10 of 219

You may also start an advanced similarity search for this article.